AGM
TVGNW icon

Alpine Global Management’s Tevogen Bio Warrant TVGNW Stock Holding History

Alpine Global Management’s Portfolio TVGNW Stock Details TVGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-60,800
Closed – – 429
2022
Q4 		$0 Hold
60,800
– – ﹤0.01% 549
2022
Q3 		$7K Buy
60,800
+2,800
+5% +$404 ﹤0.01% 207
2022
Q2 		$9K Buy
+58,000
New +$13.7K ﹤0.01% 266

Other funds holding TVGNW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return

Alpine Global Management's TVGNW Position: Q1 2023 in Review

Alpine Global Management sold out of Tevogen Bio Warrant (TVGNW) in Q1 2023, closing a stake of 60,800 shares.

Alpine Global Management first reported a position in TVGNW in Q2 2022 and held it in 3 quarters. The position peaked at $9K in Q2 2022. 55 funds tracked by Wall St. Rank hold TVGNW as of Q1 2023.

  • Alpine Global Management reported no remaining Tevogen Bio Warrant position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 60,800 Tevogen Bio Warrant shares in Q1 2023.
  • Alpine Global Management first reported a position in Tevogen Bio Warrant in Q2 2022 and held it in 3 quarters.
  • Alpine Global Management's Tevogen Bio Warrant position peaked at $9K in Q2 2022.
  • 55 funds tracked by Wall St. Rank held Tevogen Bio Warrant as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.